G6PD and nonpapillary renal cell carcinoma: The G6PD competitive activity inhibitor 6-aminonicotinamide (6-AN), a nicotinamide analog [43], was first tested in 786-O cells, one of the most highly cited cell lines that exactly clustered with ccRCC and commonly used for xenografts studies [39].